WHO and UNICEF Premix Standards for Therapeutic Foods

Therapeutic food programmes depend on micronutrient premixes that perform consistently under demanding public health conditions. In ready-to-use therapeutic foods, fortified blended foods, and other products used for severe and moderate acute malnutrition, premix quality directly affects nutrient delivery, product safety, shelf life, and programme credibility. WHO and UNICEF expectations are therefore not limited to nutrient labels alone. They extend to raw material controls, manufacturing hygiene, contaminant limits, analytical verification, packaging integrity, traceability, and supplier qualification. For food manufacturers and ingredient suppliers serving humanitarian and institutional channels, understanding these standards is essential not only for procurement success but also for risk management across domestic and export markets.

For Indian manufacturers, this topic has added significance. India has strong capabilities in micronutrient premix production, food processing, and contract manufacturing for nutrition interventions. At the same time, products intended for therapeutic feeding may need to satisfy multiple layers of requirements: FSSAI regulations, buyer specifications, Codex-aligned principles, importing country rules, and programme-specific technical standards. A premix that is acceptable for general fortification may still be unsuitable for therapeutic food if its vitamin forms, mineral particle characteristics, microbiological quality, or stability profile do not match the application. That is why WHO and UNICEF guidance should be read as an operational quality framework rather than a simple ingredient checklist.

What WHO and UNICEF standards are designed to control

In therapeutic food programmes, the purpose of premix standards is to ensure that vulnerable populations receive predictable, safe, and bioavailable micronutrients through products manufactured at scale. WHO guidance on the management of severe acute malnutrition and UNICEF procurement requirements for specialized nutritious foods align around a few core principles: nutrients must be present at the intended levels at end of shelf life, ingredients must be safe and suitable for the target population, and manufacturing systems must prevent quality drift from batch to batch. This is especially important because therapeutic foods are often used in emergency settings where storage conditions are variable and clinical dependence on the product is high.

These standards typically address the identity and purity of each vitamin and mineral source, the overall premix composition, carrier suitability, segregation controls, and validated methods for sampling and analysis. Programmes also pay close attention to nutrient interactions. For example, iron source selection can affect oxidation and sensory stability, while vitamin A and certain B vitamins can be sensitive to heat, oxygen, and humidity. Premix design must therefore support both nutrition science and process compatibility. In practice, a compliant premix is one that can survive transport, warehousing, blending, and finished product shelf life without causing unacceptable losses or product defects.

Core premix specifications in therapeutic food applications

A therapeutic food premix specification normally begins with a defined nutrient profile linked to the finished product standard. This includes target levels, acceptable overages, chemical forms, and any restrictions on substitutions. Overages are especially important because vitamins degrade over time and during processing, but excessive overages can create compliance and safety concerns. Buyers often require a clear rationale for overage design based on real stability data rather than broad assumptions. Particle size distribution, bulk density, flow properties, and carrier composition also matter because they influence blending uniformity in low-dose applications where poor dispersion can lead to major nutrient variability in the final food.

Purity and contaminant control are equally central. WHO and UNICEF-aligned procurement expectations generally require micronutrient raw materials that comply with recognized pharmacopeial, food chemical, or internationally accepted food-grade standards. Heavy metals such as lead, arsenic, cadmium, and mercury must be tightly controlled, particularly for mineral ingredients. Residual solvents, pesticide residues, dioxins, and other contaminants may also be reviewed depending on raw material origin and programme requirements. In addition, allergen status, GMO declaration where relevant, and the absence of prohibited substances can become part of the supplier documentation package, especially when the finished product is exported or procured by multilateral agencies.

Vitamin and mineral form selection

Not all nutrient forms are interchangeable in therapeutic foods. The selected form must balance bioavailability, sensory neutrality, compatibility with fats or proteins, and oxidative stability. For instance, encapsulated or specially stabilized forms may be preferred for certain vitamins to reduce losses during storage. Mineral choices can influence color, rancidity risk, and interactions with lipid components in ready-to-use therapeutic food. Procurement teams should verify that the premix supplier has documented justification for each form used, including source standard, assay range, and known incompatibilities. A change from one approved form to another should be handled through formal change control, not routine substitution based on availability alone.

Microbiological and physical quality expectations

Although premixes are low-moisture ingredients, microbiological quality still matters because they enter foods intended for medically vulnerable groups. Specifications may include total plate count, yeast and mould, coliforms, and the absence of key pathogens such as Salmonella in defined sample units. Physical quality parameters such as moisture, caking tendency, foreign matter, and sieve profile are also important because they affect both handling and homogeneity. In many therapeutic food factories, premix is added in relatively small percentages, so any lumping, segregation, or inconsistent particle characteristics can translate into nutrient hotspots or under-fortified portions. Robust physical specifications are therefore not cosmetic; they are part of dosage control.

Supplier qualification and manufacturing system requirements

WHO and UNICEF procurement practice places strong emphasis on the quality system behind the premix, not only the certificate of analysis attached to a lot. Manufacturers are expected to operate under documented GMP, hazard analysis and preventive control systems, calibrated equipment, validated cleaning procedures, and controlled storage conditions. Traceability should reach back to individual vitamin and mineral lots, carriers, and processing aids. For institutional programmes, the ability to reconstruct batch history quickly is critical in the event of a field complaint, recall, or nutritional nonconformance. This is one reason why supplier audits often examine documentation discipline as closely as they examine laboratory capability.

Premix plants serving therapeutic food programmes should also demonstrate strong controls for weighing accuracy, line clearance, cross-contact prevention, and environmental monitoring where appropriate. Because premixes contain many low-inclusion components, small weighing errors can materially shift nutrient outcomes. Electronic batch records, barcode-based dispensing, and independent verification steps are useful safeguards. Sampling plans should be scientifically justified because micronutrients are not always evenly distributed if the process is weak. Buyers increasingly expect evidence that blending time, mixer loading, sieve integrity, and hold times have been validated. A supplier that cannot explain process capability in operational terms will struggle to meet the scrutiny applied in humanitarian nutrition supply chains.

For Indian manufacturers, FSSAI licensing and compliance form the regulatory baseline, but international therapeutic food tenders usually expect more than domestic legal minimums. A facility may need to present GMP certifications, food safety management certifications, product specifications, stability reports, raw material origin statements, and audit responses in a format aligned with global procurement systems. Export-oriented suppliers should also understand destination-country import documentation and any buyer-mandated social compliance or ethical sourcing declarations. In short, quality acceptance in therapeutic food programmes is built on layered assurance: national compliance, technical conformity, and procurement readiness.

Testing, stability, and documentation that buyers look for

Analytical verification is a central pillar of premix acceptance. A credible supplier should provide a detailed certificate of analysis for each batch covering identity, assay, and key physical and microbiological parameters. However, buyers often go beyond release testing. They may ask for method references, laboratory accreditation status, uncertainty information, and evidence that test methods are appropriate for the matrix and concentration range. For vitamins present at low levels, analytical complexity can be significant, and poor method suitability can generate misleading results. Contract testing laboratories should therefore be selected carefully, and any differences between premix assay and finished product assay should be scientifically interpreted.

Stability data is another area where many suppliers underestimate buyer expectations. Therapeutic food programmes need confidence that nutrient levels remain within specification through the declared shelf life of the finished product, often under challenging storage conditions. This means premix suppliers should ideally support customers with accelerated and real-time stability data, or at minimum, robust historical evidence for comparable formulations and packaging systems. Nutrient retention depends on more than the premix alone; fat quality, water activity, oxygen exposure, and process temperature in the finished food all matter. Even so, a well-characterized premix with justified overages and protective packaging significantly reduces programme risk.

Documentation should be complete, current, and audit-ready. Typical files include product specifications, composition statements, allergen and GMO declarations, shelf-life statements, safety data where relevant, certificates of origin, packaging specifications, and storage recommendations. Change control documentation is particularly important. If there is any alteration in vitamin source, mineral grade, carrier, manufacturing site, analytical method, or packaging format, customers in therapeutic food programmes usually expect prior notification and technical review. A supplier relationship built on undocumented substitutions can quickly become noncompliant, even if the nominal nutrient profile appears unchanged.

Packaging, storage, and transport controls

Premix packaging for therapeutic food use must protect against moisture, oxygen, light, and physical damage. Multi-layer barrier packs, sealed liners, tamper-evident closures, and clearly legible lot coding are common expectations. Storage instructions should specify temperature and humidity limits, stacking guidance, and first-expiry-first-out controls. Transport conditions also matter, especially in Indian summers and in export routes involving long dwell times at ports. If a supplier claims a given shelf life but uses packaging that allows moisture ingress or provides no data on tropical storage performance, procurement teams should treat that as a material risk. Packaging is part of nutrient protection, not an administrative afterthought.

Practical implications for Indian and export-focused manufacturers

Indian food manufacturers participating in therapeutic food or institutional nutrition supply chains should align premix procurement with a formal technical approval process. Start with a product-specific specification linked to the finished food standard rather than buying a generic multivitamin-mineral blend. Then evaluate suppliers on compliance history, audit readiness, raw material control, analytical capability, and responsiveness to documentation requests. Commercial price matters, but in this category the total cost of failure is much higher than the unit cost difference between suppliers. A rejected batch, failed nutrient retention study, or delayed UNICEF-linked shipment can erase any short-term purchasing gain.

Manufacturers should also involve regulatory, quality, and process teams early when developing or reformulating therapeutic foods. Premix compatibility with the production line, fat system, thermal exposure, and packaging format should be tested before commercialization. This is particularly relevant for Indian facilities expanding from general fortified foods into humanitarian or clinical nutrition applications. The specifications are tighter, the documentation burden is heavier, and the end users are more vulnerable. A disciplined premix qualification process helps bridge that transition and supports smoother engagement with international agencies, NGOs, and export buyers who expect evidence-based quality management rather than broad declarations of compliance.

For ingredient suppliers, the strongest position is to offer not just a formulation but a complete quality dossier. That includes clear nutrient rationale, validated manufacturing controls, contaminant risk assessment, retained sample policy, and stability support. It is also useful to define service parameters such as lead times, minimum order quantities, batch size consistency, and emergency supply capability, since therapeutic food programmes may operate under surge demand conditions. Buyers value operational reliability as much as technical conformance. Premix supply interruptions can halt production of life-saving foods, so supply chain resilience is now part of quality in practical terms.

A useful internal benchmark is to ask whether the premix would withstand scrutiny from three different reviewers: a procurement auditor, a quality manager, and a nutrition programme specialist. The procurement auditor will examine traceability and documents, the quality manager will challenge process control and test validity, and the nutrition specialist will focus on nutrient suitability and retention in the target product. If the same dossier satisfies all three perspectives, the supplier is much more likely to succeed in WHO and UNICEF-aligned programmes. That cross-functional readiness is especially important for Indian exporters seeking long-term participation in global therapeutic nutrition supply chains.

The practical next step for manufacturers is straightforward: review every therapeutic food premix against a written checklist covering nutrient forms, assay tolerances, contaminants, microbiology, packaging, traceability, stability support, and change control. Where gaps exist, close them before tendering or scale-up rather than after a buyer query or batch deviation. In therapeutic food programmes, premix quality is not a supporting detail; it is a frontline control point for clinical performance, product compliance, and uninterrupted supply. Companies that treat WHO and UNICEF standards as an integrated operating discipline, and not just a procurement hurdle, will be far better positioned to serve both Indian nutrition initiatives and global export markets responsibly.